Okamoto Shinichiro
Division of Hematology, Department of Medicine, Keio University School of Medicine.
Nihon Rinsho. 2008 Mar;66(3):575-83.
Stem cell transplantation is an effective treatment for anemia associated with stem cell disorders such as severe aplastic anemia, myelodysplastic syndrome. Long-term survival rates after transplantation for those diseases range from less than 40% to more than 80%. The rates are significantly affected by recipient's age, HLA disparity between donor and recipient, sources of stem cells, and disease status. Results are best in younger patients transplanted with bone marrow from HLA-identical sibling at the early course of the diseases. The decision of whether and at what point to proceed to transplantation should be made early after diagnosis, based upon the consideration of a survival rate with reasonable quality of life expected with transplantation and other therapeutic approaches.
干细胞移植是治疗与干细胞疾病相关贫血的有效方法，如严重再生障碍性贫血、骨髓增生异常综合征。这些疾病移植后的长期生存率从不到40%到超过80%不等。这些比率受受者年龄、供受者之间的人类白细胞抗原（HLA）差异、干细胞来源和疾病状态的显著影响。对于疾病早期接受来自HLA相同同胞的骨髓移植的年轻患者，结果最佳。是否以及何时进行移植的决定应在诊断后尽早做出，这要基于对移植及其他治疗方法预期的具有合理生活质量的生存率的考虑。
